Internal hemorrhoid

Summary

Internal hemorrhoid (MONDO:0004873) is a disease and 13 clinical trials. Top therapeutic interventions include nitroglycerin and iferanserin. A subtype of hemorrhoid — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 13

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	internal hemorrhoid
Mondo ID	MONDO:0004873
DOID	DOID:9749
NCIT	C35319
SNOMED CT	90458007
UMLS	C0265034
MedGen	75549
Is cancer (heuristic)	no

Also known as: internal hemorrhoid

Disease family

This is a subtype of hemorrhoid. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › vein disorder › varicose disease › pelvic varices › hemorrhoid › internal hemorrhoid

Related subtypes (1): perianal hematoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 13.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE3	2
PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07391501	PHASE4	NOT_YET_RECRUITING	Nitroglycerin Ointment for Pain Relief After Endoscopic Hemorrhoid Band Ligation
NCT01355874	PHASE3	TERMINATED	Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids
NCT01533363	PHASE3	COMPLETED	Study About Patient Comfort and Long-term Outcome After Stapled Hemorrhoidopexy
NCT01913158	PHASE2	COMPLETED	Safety and Efficacy Study of Anucort HC TM 25mg Rectal Suppositories to Treat Symptomatic Internal Hemorrhoids
NCT03335774	PHASE2	COMPLETED	Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids
NCT04169152	Not specified	RECRUITING	CAES for Internal Hemorrhoids and Rectal Prolapse
NCT06106269	Not specified	RECRUITING	Outcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids
NCT07179601	Not specified	RECRUITING	Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)
NCT07333040	Not specified	NOT_YET_RECRUITING	HELO Trial: Energy-Based Therapies vs. Conventional Hemorrhoidectomy for Grade III Hemorrhoids
NCT07520734	Not specified	NOT_YET_RECRUITING	Clinical Outcomes After Laser Hemorrhoidoplasty
NCT03917056	Not specified	UNKNOWN	Cap-assisted Endoscopic Sclerotherapy for Internal Hemorrhoids and Rectal Prolapse
NCT06031740	Not specified	UNKNOWN	A Comparison of Flexible Endoscopic Polidocanol Liquid and Foam Sclerotherapy in Cirrhotic Patients With Bleeding From Internal Hemorrhoids
NCT06250140	Not specified	UNKNOWN	Recurrence Rate of Minimally Invasive Endoscopic Treatment of Internal Hemorrhoids

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NITROGLYCERIN	4	1
IFERANSERIN	3	1